MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

With its colourful history of regimes, languages and cultures, Malta has forever been a place known for maintaining its own identity and focus within the evolving European sphere.

Since the island gained its independence in 1964, it has done more and more to distinguish itself as a significant global presence with the ability to influence global markets. With the decision to lead the charge on working with, encouraging and facilitating the cannabis industry in 2016, Malta has truly taken a step forward, by creating a global hub of a potentially massive industry.
MGC Pharma first became aware of these interests and efforts in 2017, and quickly began to recognise what the residents of this island have known for a very long time: this is a very special place, and there are plenty of reasons to base yourself here.

Largest GMP Phyto-cannabinoid focused manufacturing facility in the world

Once complete, the Maltese facility is expected to be the largest GMP phytocannabinoid focused manufacturing facility in the world, with capacity to produce fully compliant medicines at a rate of thousands of units an hour.

MGC Pharma and Malta: perfect together?

The facility under construction in Malta (which is expected to be operational in mid-2021) will be significantly larger than MGC’s existing facility in Slovenia and will be the primary hub for the MGC’s manufacturing operations.

Final stages of listing the Company’s shares on the London Stock Exchange

MGC Pharmaceuticals Ltd, a European based and Australian listed bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines, is pleased to announce it is in the final stages of listing the Company’s shares on the Standard Segment of the Main Market of the London Stock Exchange. As part of the listing process, the Company has appointed Turner Pope and intends to raise gross proceeds of approximately £5m via institutional and other sophisticated investors in the United Kingdom.

Visit MGC Pharma

Leave a Reply

Your email address will not be published. Required fields are marked *